Abingworth

38 Jermyn Street, SW1Y 6DT London, England, United Kingdom
Investor type VC
Founded 1973
AUM -
Location United Kingdom

Profile

Vast experience: check. Deep expertise: check. Easy accessibility: check. After decades of investing from offices in the most important centers of biotechnology worldwide, Abingworth offers entrepreneurs an unmatched combination of all three of these key attributes. We partner with entrepreneurs to create companies that have a significant impact on patients’ lives. Participating at all stages of development and across all sectors, we take a broad strategic approach to investing in life sciences. BROAD STRATEGIC APPROACH Within the life sciences market we participate in a wide range of opportunities spanning therapeutics, medical devices, diagnostics, instrumentation and software. We invest in seed stage projects, technology platforms, preclinical and clinical assets as well as approved and marketed products. Supporting private and public companies, we aim to partner with the most innovative entrepreneurs to address significant unmet needs in healthcare. Vast experience: check. Deep expertise: check. Easy accessibility: check. After decades of investing from offices in the most important centers of biotechnology worldwide, Abingworth offers entrepreneurs an unmatched combination of all three of these key attributes. We can help attract talent for boards and leadership teams, choose drug targets for novel platforms, devise plans for clinical development, navigate legal issues, advise on PR strategy and think through corporate development and exit strategies. Adding to our own knowledge, we have a wide network of leading scientific and industry experts. Our collective experience is offered to all portfolio companies.

Industry focus

Pharmaceuticals Medical Devices Biotechnology Healthcare Services HealthTech Software AI MedTech Technology Life Sciences Machine Learning (ML)

Investment preferences

Investment Ticket

$0-1 m

Investment Horizon

3-5 years

Investment Stage

Seed

Growth

Round A and B

Exit Strategy

Sale to strategic investor

IPO

Region focus

North America Europe

Contacts

Name
Title
E-mail
Social

Name

Name

Title

Title

E-mail

email@email.com

Social

Name

Name

Title

Title

E-mail

email@email.com

Social

Name

Name

Title

Title

E-mail

email@email.com

Social

If there are no contacts of this investor, please write to us, we will try to find them as soon as possible and get back to you!